Literature DB >> 21455369

Reemergence of positive symptoms of schizophrenia during the course of treatment with risperidone.

P Bajaj1, N Nihalani, N Shah, N Desai, V Shinde, N Raut.   

Abstract

Thirty patients suffering from schizophrenia (diagnosed as per DSM-IV criteria), for more than 2 years and having predominant negative symptoms were started on risperidone (2-10 mg/day) and were followed up over a period of 16 weeks. The improvement was assessed using PANSS (Positive and Negative Syndrome Scale).During this 16 weeks follow up, it was interestingly noted that though there was a significant improvement in negative symptoms in all the patients, in 7 patients there was a reemergence of positive symptoms. Four patients had increase in rating on suspiciousness and hostility and two patients reported auditory hallucinations. One patient developed delusions and conceptual disorganization along with suspiciousness and hostility.

Entities:  

Keywords:  Risperidone; positive symptoms; schizophrenia

Year:  1999        PMID: 21455369      PMCID: PMC2962850     

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


  15 in total

Review 1.  The positive-negative distinction in schizophrenia. Review of natural history validators.

Authors:  T H McGlashan; W S Fenton
Journal:  Arch Gen Psychiatry       Date:  1992-01

2.  BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.

Authors:  M Volonté; E Monferini; M Cerutti; F Fodritto; F Borsini
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

3.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

Review 4.  Dopamine in schizophrenia: a review and reconceptualization.

Authors:  K L Davis; R S Kahn; G Ko; M Davidson
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

5.  Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

Authors:  G Bondolfi; H Dufour; M Patris; J P May; U Billeter; C B Eap; P Baumann
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

6.  Reemergence of positive symptoms after initial response to risperidone.

Authors:  D D Cung; G L Stimmel
Journal:  Pharmacotherapy       Date:  1997 Mar-Apr       Impact factor: 4.705

7.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

Authors:  G Chouinard; B Jones; G Remington; D Bloom; D Addington; G W MacEwan; A Labelle; L Beauclair; W Arnott
Journal:  J Clin Psychopharmacol       Date:  1993-02       Impact factor: 3.153

8.  The composition of the negative syndrome of chronic schizophrenia.

Authors:  D A Kibel; I Laffont; P F Liddle
Journal:  Br J Psychiatry       Date:  1993-06       Impact factor: 9.319

9.  Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.

Authors:  A Claus; J Bollen; H De Cuyper; M Eneman; M Malfroid; J Peuskens; S Heylen
Journal:  Acta Psychiatr Scand       Date:  1992-04       Impact factor: 6.392

10.  Risperidone in the treatment of schizophrenia.

Authors:  S R Marder; R C Meibach
Journal:  Am J Psychiatry       Date:  1994-06       Impact factor: 18.112

View more
  2 in total

1.  Schizophrenia research: Indian scene in last decade.

Authors:  Ajit Avasthi; Gagandeep Singh
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

2.  Research on antipsychotics in India.

Authors:  Ajit Avasthi; Munish Aggarwal; Sandeep Grover; Mohd Khalid Rasheed Khan
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.